NLR

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Retrieved on: 
Wednesday, December 6, 2023
Survival, Probability, Allogenic succession, Kaplan–Meier estimator, BCT, NLR, Cancer, Therapy, CPI, University, Lymphocyte, Toxicity, TSX, Patient, Pharmaceutical industry

32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.

Key Points: 
  • 32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.
  • PHILADELPHIA and VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT™ in combination with an immune check point inhibitor (CPI).
  • The data is being revealed at the 2023 San Antonio Breast Cancer Symposium® held at Henry B. Gonzalez Convention Center, San Antonio, TX.
  • In summary, the consistent topline survival and clinical benefits support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and support the ongoing pivotal study of our combination regimen in the treatment of advanced metastatic breast cancer.

Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma

Retrieved on: 
Monday, November 20, 2023
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Glioblastoma, Neuro-oncology, Patient, SNO, PFS, ITT, NLR, Pharmaceutical industry

Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting, which was held in Vancouver, British Columbia, Canada, from November 15-19, 2023.

Key Points: 
  • Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting, which was held in Vancouver, British Columbia, Canada, from November 15-19, 2023.
  • At the meeting, Imvax presented new data from its Phase 1b study of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM).
  • Additional data presented highlighted a significant decrease at various study points of the average neutrophil-to-lymphocyte (NLR) ratio.
  • The NLR may be a potential biomarker for positive clinical outcomes, which will be further explored as part of Imvax’s ongoing Phase 2b study in ndGBM patients.

Ad Astra Diagnostics receives 510(k) clearance of QScout™ hematology analyzer, the first to report measures of infection and severity at point-of-care

Retrieved on: 
Thursday, December 7, 2023
Host, Food, ICU, Allergy, Hematology, Leukemia, FDA, AAD, Caregiver, Human services, Flow cytometry, MD, Infection, NLR, Administration, IGS, Granulocyte, White blood cell, WBC, Cell, Health, Sparrow Health System, Medical device, Sepsis, Research

MORRISVILLE, N.C., Dec. 7, 2023 /PRNewswire/ -- Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Key Points: 
  • QScout™ is the first hematology platform designed for simple, fast operation at the point-of-care.
  • It provides lab-grade, patient-side results that caregivers use to screen for health conditions including infection, leukemia, and other blood-related cancers, allergies, and many more.
  • Elevated levels of IGs have been shown to differentiate sepsis earlier than commonly used measures like lactate and procalcitonin1.
  • Additionally, NLR is an increasingly important predictor of poor health outcomes that gained greater use during the pandemic.

Ad Astra Diagnostics receives 510(k) clearance of QScout™ hematology analyzer, the first to report measures of infection and severity at point-of-care

Retrieved on: 
Thursday, November 16, 2023
Sepsis, Food, ICU, Allergy, Hematology, Leukemia, FDA, AAD, COVID-19, Flow cytometry, MD, Infection, NLR, IGS, Granulocyte, White blood cell, Innovation, WBC, Cell, Health, Sparrow Health System, Procalcitonin, Vaccine, Medical device, Research

MORRISVILLE, N.C., Nov. 16, 2023 /PRNewswire/ -- Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Key Points: 
  • QScout™ is the first hematology platform designed for simple, fast operation at the point-of-care.
  • It provides lab-grade, patient-side results to screen for health conditions including infection, leukemia and other blood-related cancers, allergies, and many more.
  • Additionally, NLR is an increasingly important predictor of poor health outcomes, which gained greater use during the pandemic.
  • Sepsis, the body's extreme response to infection, is a life-threatening medical emergency that happens when infection triggers a chain reaction throughout the body.

EQS-News: Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases

Retrieved on: 
Thursday, July 6, 2023
Asos, Asthma, Central nervous system, University, Chronic kidney disease, Arthritis, Fever, NOMID, FCAS, Survival, Autoinflammatory diseases, NLRP3, Quality of life, MWS, University of California, San Diego Performance-Based Skills Assessment, Inflammation, Life expectancy, CAPS, Journal of Immunology, Inflammatory bowel disease, Hyperkinesia, Skin, Journal, Patient, NLR, Fatty liver disease, ASO, Weight gain, Fine chemical, Vaccine, Pharmaceutical industry

Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.

Key Points: 
  • Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.
  • CAPS are a spectrum of autoinflammatory diseases caused by activating mutations in the NLRP3 gene.
  • The activity of NLRP3-ASO was tested in an in vivo NOMID disease model; NOMID is the most severe form of CAPS.
  • After systemic ASO treatment, life expectancy was significantly increased, with weight gains and reductions in the severity of skin lesions, showing an overall reduction in systemic inflammation.

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract (summary), Rituximab, Obinutuzumab, BGNE, EU, Doctor of Philosophy, Hepatocellular carcinoma, Lymphoid leukemia, NA, Lenalidomide, OS, Trae tha Truth, Head, Toxicity, Multimedia, BCLC, Lung cancer, ASCO, PLR, Incidence, SSE, OX40, American Society of Clinical Oncology, Patient, Sorafenib, NLR, Annual general meeting, Bone marrow, Abstract, Society, ORR, Tislelizumab, Pharmaceutical industry, Vaccine, Flour, BeiGene

These results include data for BeiGene’s cornerstone therapies, BRUKINSA® (zanubrutinib) and tislelizumab, as well as early results for BeiGene’s OX40 agonist and BCL-2 inhibitor.

Key Points: 
  • These results include data for BeiGene’s cornerstone therapies, BRUKINSA® (zanubrutinib) and tislelizumab, as well as early results for BeiGene’s OX40 agonist and BCL-2 inhibitor.
  • These results will be presented on Monday, June 5, as poster presentations from 8:00-11:00 a.m. CT. (Abstracts #4082 and #4083).
  • BGB-11417 monotherapy also showed promising initial efficacy results in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma, with patients achieving responses at lower dose levels.
  • These results will be presented on Monday, June 5, as a poster presentation from 8:00-11:00 a.m. CT (Abstract #7558).

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Retrieved on: 
Wednesday, April 19, 2023
NOD2, AACR, Therapy, Neoplasm, Cancer, American Association for Cancer Research, TLR9, NSAID, Breast, Research, LDC, TLR4, TLR2, Patient, NLR, TLR8, Poster, Metastasis, Pharmaceutical industry, Vaccine

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.

Key Points: 
  • NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.
  • The poster, titled, “ A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy ,” authored by Michael J. Newman, Ph.D., the Company’s Founder and Chief Scientific Officer, was presented Tuesday, April 18, 2023.
  • Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody.
  • Importantly, our results demonstrate the potential for activity in multiple solid tumor indications with high unmet need and the flexibility to be combined with a wide variety of synergy partners.

Greenberg Traurig Immigration Practice, Attorneys Recognized as National Law Review 'Go-To Thought Leaders'

Retrieved on: 
Wednesday, December 28, 2022
Organization, Tax, LLP, Corporation, U.S. News & World Report, New York City Regional Center, Immigration, Blog, Kalmykov, Social media, Alliance of Business Immigration Lawyers, Immigration law, The National Law Review, Labour, Center for Resource Solutions, News, Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, Gene Hermanski, Corporate security, Business, Philippine Senate Committee on Labor, Employment and Human Resources Development, Reiff, Classification, AM, Database, Congress, Real estate, EB-5, NLJ, NLR, Clothing, Audit, Video game, Greenberg Traurig

NEW YORK, Dec. 28, 2022 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP was recognized for the third time in five years as a National Law Review (NLR) "2022 Go-To Thought Leader" for Immigration Law for its coverage of the latest EB-5 classification news and updates. Shareholders Dillon R. Colucci, Jennifer Hermansky, Kate Kalmykov, and Laura Foote Reiff were highlighted for their work writing for the firm's EB-5 Insights blog.

Key Points: 
  • Global law firm Greenberg Traurig, LLP was recognized for the third time in five years as a National Law Review (NLR) "2022 Go-To Thought Leader" for Immigration Law for its coverage of the latest EB-5 classification news and updates.
  • NEW YORK, Dec. 28, 2022 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP was recognized for the third time in five years as a National Law Review (NLR) " 2022 Go-To Thought Leader " for Immigration Law for its coverage of the latest EB-5 classification news and updates.
  • The team is composed of active thought leaders who write regularly for Greenberg Traurig's Immigration blogs: Inside Business Immigration and EB-5 Insights .
  • The team is composed of active thought leaders who write regularly for Greenberg Traurig's Immigration blogs: Inside Business Immigration and EB-5 Insights .

The National Law Review Announces its 2022 "Go-To Thought Leader" Award Recipients, Honoring Excellence in Legal News and Analysis

Retrieved on: 
Monday, December 19, 2022
The National Law Review, News, Publication, Labour government, Editorial, Going Clear (book), NLR, Medical device, Pharmaceutical industry

CHICAGO, Dec. 19, 2022 /PRNewswire-PRWeb/ -- The National Law Review (NLR) "Go-To Thought Leadership Awards" recognizes 75 exceptional authors and legal organizations for their reporting of complex legislative and litigation news, as well as their strategic insight and overall industry knowledge. Less than 1% of the National Law Review contributing authors are recognized each year.

Key Points: 
  • The recipients were selected by the National Law Review's editors from a pool of thousands of contributed legal news and analysis articles and highlight the unique talents of less than 1% of our contributing authors.
  • CHICAGO, Dec. 19, 2022 /PRNewswire-PRWeb/ -- The National Law Review (NLR) "Go-To Thought Leadership Awards" recognizes 75 exceptional authors and legal organizations for their reporting of complex legislative and litigation news, as well as their strategic insight and overall industry knowledge.
  • Less than 1% of the National Law Review contributing authors are recognized each year.
  • Please join us in congratulating the National Law Review 2022 Go-To Thought Leader Leadership Awards recipients:

Commodities Offer Another Option for Investors Amidst Turbulent Market Conditions

Retrieved on: 
Thursday, June 16, 2022
NLR, Gold, Sierra Madre, Contextual advertising, OTCQX, CSE, Marketing, Rodrigo de la Guitarra, Policy, HL, Social media, Disclosure, Privacy policy, Privacy, MNI - Market News, Bias, CEO, Editorial, News, Press release, CDE, OTC, Use, Batopilas, Twitter, Silver, Federal Reserve, Carbonate, Magnetism, NSR, Hecla Mining, CDN, Federal, Coeur, Comparison, Santa Eulalia District, Spring, Instagram, FSM, NYSE, NE, Coeur Mining, Financial News, Advertising, CRD, Senior, Vein, Company, First Majestic Silver, Research, Growth, AG, Century, Goal, Mining, Uranium, Public relations, Efrain Guigui, Politics, Copper, Exploration, Sunbird, Sgula

NEW YORK, June 16, 2022 /PRNewswire/ -- It's often said that interest rates have a significant impact on the prices of gold and silver. Generally, this would appear to be true. The theory behind the claim makes sense; for example, if interest rates were to increase, that would in turn make the appeal of bonds and savings accounts go up as well, and demand for physical assets go down. In reality, though, there is no real statistical evidence to show any consistency to that claim, mostly because there are numerous factors that also affect the price of these commodities. Reyna Silver Corp. (OTC: RSNVF) (TSX-V: RSLV), First Majestic Silver Corp. (NYSE: AG), Fortuna Silver Mines Inc. (NYSE: FSM), Hecla Mining Company (NYSE: HL), Coeur Mining, Inc. (NYSE: CDE).

Key Points: 
  • One of the reasons for this is that gold and silver markets largely operate on investors' expectations for the future.
  • Now, as the inflation and supply problems affect the economy negatively, there is a need to hedge against the market with a safe haven asset.
  • The results show zoning of Copper, Lead-Zinc, and Silver and are interpreted to indicate a CRD mineralization center at depth.
  • FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news.